scispace - formally typeset
Journal ArticleDOI

Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery.

Konstantinos Avgoustakis
- 30 Sep 2004 - 
- Vol. 1, Iss: 4, pp 321-333
TLDR
The ability of the PLA-Peg and PLGA-PEG nanoparticles to evade rapid phagocytocis has extended the range of sites within the body that the nanoparticles can reach, which has significant implications with regard to their application in controlled drug delivery and targeting.
Abstract
The preparation, properties and potential applications in drug delivery of biocompatible and biodegradable PLA-PEG and PLGA-PEG nanoparticles are discussed. PLA-PEG and PLGA-PEG nanoparticles have been produced by emulsification-solvent evaporation, solvent displacement and salting out methods. The nanoparticles can be stored as freeze-dried powders, but an adequate amount of a suitable lyoprotectant should be added prior lyophilisation to prevent nanoparticle aggregation and retain nanoparticle redispersibility. The nanoparticles have a core-shell structure with a PLA core and a PEG coating. Their basic colloidal properties and degradation depend on copolymer composition. The PLA-PEG and PLGA-PEG nanoparticles exhibit prolonged blood circulation following intravenous administration to animals. The composition of the nanoparticles determine their biodistribution properties, probably through its effects on the effectiveness of the PEG steric barrier and the size of the nanoparticles. The ability of the PLA-PEG and PLGA-PEG nanoparticles to evade rapid phagocytocis has extended the range of sites within the body that the nanoparticles can reach, which has significant implications with regard to their application in controlled drug delivery and targeting. The PLA-PEG and PLGA-PEG nanoparticles can be loaded with a variety of bioactive agents achieving satisfactory loading, especially in the case of hydrophobic drugs. The nanoparticles have been investigated for the treatment of infectious diseases and cancer, the intravenous and mucosal delivery of proteins, and oligonucleotide and gene delivery. The results have been encouraging and PLA-PEG and PLGA-PEG nanoparticle formulations, improving the therapeutic potential of both established and new drugs, may be expected to be available in the near future.

read more

Citations
More filters
Patent

Multivalent synthetic nanocarrier vaccines

TL;DR: In this article, the authors proposed compositions comprising population of synthetic nanocarries that comprise different sets of antigens as well as related methods, and the invention relates, at least in part, to compositions comprising a population of synthetically available nanocars.
Journal ArticleDOI

Synthesis and in vitro evaluation of novel star-shaped block copolymers (blocked star vectors) for efficient gene delivery.

TL;DR: The transfection study on COS-1 cells showed that the polyplexes from block copolymers with cationic chain length of approximately 50,000 and a nonionic chainlength of 30,000 had the most efficient luciferase activity with minimal cellular cytotoxicity under a charge ratio of 20 (vector/pDNA).
Journal ArticleDOI

Enzymatic protection and biocompatibility screening of enzyme-loaded polymeric nanoparticles for neurotherapeutic applications.

TL;DR: It is identified that inclusion of free PEG along with PLGA-PEG polymer during the emulsification phases or replacing DCM with trichloromethane (chloroform) produced biocompatible polymeric nanoparticle formulations that still provided enzymatic protection.
Journal ArticleDOI

Controlled Synthesis of Polylactides Using Biogenic Creatinine Carboxylate Initiators

TL;DR: Two biogenetic guanidine carboxylates synthesized and structurally characterized by (1)H NMR, (13)C NMR and X-ray diffraction (XRD) analysis of the single crystals demonstrated that CRA and CRG are CR-guanidinium car boxylates in nature, and the carboxesylates are associated with the guanid inium via hydrogen bonds.
Related Papers (5)